<div id="readability-page-1"><p>B. Riley Wealth Advisors Inc. bought a new position in shares of  Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  bought 4,141 shares of the pharmaceutical company's stock, valued at approximately $1,844,000.</p><ul><li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li></ul><p>Several other large investors have also recently added to or reduced their stakes in VRTX. Activest Wealth Management acquired a new stake in shares of  Vertex Pharmaceuticals in the 1st quarter worth about $25,000.  Access Investment Management LLC bought a new stake in  Vertex Pharmaceuticals in the second quarter worth about $27,000.  Legacy Investment Solutions LLC acquired a new position in  Vertex Pharmaceuticals in the second quarter worth approximately $29,000.  Flaharty Asset Management LLC bought a new position in shares of  Vertex Pharmaceuticals in the first quarter valued at $32,000.  Finally, American National Bank &amp; Trust lifted its position in shares of  Vertex Pharmaceuticals by 515.4% during the 2nd quarter. American National Bank &amp; Trust now owns 80 shares of the pharmaceutical company's stock valued at $36,000 after acquiring an additional 67 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds. </p><div><p><span></span><span>Get <strong>Vertex Pharmaceuticals</strong> alerts:</span></p></div><h2>Vertex Pharmaceuticals Stock Up 1.4%</h2><p>VRTX stock opened at $452.04 on Monday. The company has a 50 day moving average of $426.51 and a two-hundred day moving average of $425.47. The company has a market cap of $114.69 billion, a price-to-earnings ratio of 31.88 and a beta of 0.32. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.68. </p><ul><li>Best Biotech Stocks to Buy in 2025</li></ul><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, topping analysts' consensus estimates of $4.58 by $0.22. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. Vertex Pharmaceuticals's revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period in the prior year, the business posted $4.38 earnings per share.  On average, research analysts anticipate that  Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of brokerages have recently issued reports on VRTX. Leerink Partnrs raised Vertex Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, September 25th. Citigroup boosted their price objective on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, October 2nd. Barclays upped their price objective on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the company an &#34;equal weight&#34; rating in a research note on Tuesday, November 4th. Royal Bank Of Canada dropped their target price on shares of Vertex Pharmaceuticals from $423.00 to $415.00 and set a &#34;sector perform&#34; rating on the stock in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus cut their price target on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a &#34;hold&#34; rating on the stock in a report on Tuesday, November 4th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned  a Buy rating and ten have assigned  a Hold rating to the company. According to MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $498.42.</p><ul><li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li></ul><p><b>View Our Latest Research Report on Vertex Pharmaceuticals</b></p><h2>Insider Transactions at Vertex Pharmaceuticals</h2><p>In other Vertex Pharmaceuticals news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the business's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $456.00, for a total value of $6,384,000.00. Following the completion of the sale, the executive vice president directly owned 37,725 shares of the company's stock, valued at $17,202,600. The trade was a 27.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman Jeffrey M. Leiden sold 63,781 shares of the firm's stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $449.20, for a total transaction of $28,650,425.20. Following the transaction, the chairman owned 24,026 shares in the company, valued at $10,792,479.20. This represents a 72.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 151,073 shares of company stock valued at $67,326,816 over the last ninety days. Company insiders own  0.20% of the company's stock. </p><h2>About Vertex Pharmaceuticals</h2> (Free Report)<p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Vertex Pharmaceuticals</li><li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>CD Calculator: Certificate of Deposit Calculator </li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li><li>How to invest in marijuana stocks in 7 steps </li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VERX

RILY

VRTX

<p>B. Riley Wealth Advisors Inc. acquired 4,141 shares of Vertex Pharmaceuticals, valued at approximately $1,844,000, during the second quarter. This acquisition was reported in their Form 13F filing with the SEC. Vertex Pharmaceuticals' stock has been performing well, with a recent price increase and positive earnings report. Several analysts have issued favorable ratings, and the company has a consensus rating of 'Moderate Buy' with a price target of $498.42.</p>

B. Riley Wealth Advisors Inc. Buys Shares of 4,141 Vertex Pharmaceuticals Incorporated $VRTX